Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Maurizio
Bendandi
Publicacions en què col·labora amb Maurizio Bendandi (20)
2021
2017
-
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Journal of Translational Medicine, Vol. 15, Núm. 1
-
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
PLoS ONE, Vol. 12, Núm. 9
2016
-
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
Oncotarget, Vol. 7, Núm. 4, pp. 4522-4530
-
MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells
Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196
-
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy
Biomaterials, Vol. 91, pp. 73-80
2015
-
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
Biomaterials, Vol. 67, pp. 274-285
2007
-
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer
Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615
-
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions
Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680
2006
-
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301
-
El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones viráles crónicas
Anales del sistema sanitario de Navarra, Vol. 29, Núm. 1, pp. 77-96
-
Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena
Clinical Cancer Research
2005
-
Critical appraisal of the current status of dendritic cell based therapy
Inmunologia, Vol. 24, Núm. 1, pp. 23-32
-
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas
Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010
2004
-
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients
Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 499-502
-
Inmunoterapia activa en el tratamiento de neoplasias hematológicas
Anales del sistema sanitario de Navarra, Vol. 27, Núm. 1, pp. 45-62
-
Past, present and future of anti-idiotype vaccination
Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23
2003
-
Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies
Clinical Cancer Research, Vol. 9, Núm. 15, pp. 5454-5464
-
Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases
Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181
2002
-
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming
Experimental Hematology, Vol. 30, Núm. 12, pp. 1355-1364